Identification of Potent Reverse Indazole Inhibitors for HPK1.

Hematopoietic progenitor kinase (HPK1), a negative regulator of TCR-mediated T-cell activation, has been recognized as a novel antitumor immunotherapy target. Structural optimization of kinase inhibitor 4 through a systematic two-dimensional diversity screen of pyrazolopyridines led to the identification of potent and selective compounds. Crystallographic studies with HPK1 revealed a favorable water-mediated interaction with Asp155 and a salt bridge to Asp101 with optimized heterocyclic solvent fronts that were critical for enhanced potency and selectivity. Computational studies of model systems revealed differences in torsional profiles that allowed for these beneficial protein-ligand interactions. Further optimization of molecular properties led to identification of potent and selective reverse indazole inhibitor 36 that inhibited phosphorylation of adaptor protein SLP76 in human PBMC and exhibited low clearance with notable bioavailability in in vivo rat studies.

[1]  S. Sawasdikosol,et al.  A perspective on HPK1 as a novel immuno-oncology drug target , 2020, eLife.

[2]  I. Kariv,et al.  Development of High-Throughput Assays for Evaluation of Hematopoietic Progenitor Kinase 1 Inhibitors , 2020, SLAS discovery : advancing life sciences R & D.

[3]  D. Dimitrov,et al.  Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies. , 2020, Cancer cell.

[4]  C. Raab,et al.  Integrating the Impact of Lipophilicity on Potency and Pharmacokinetic Parameters Enables the Use of Diverse Chemical Space during Small Molecule Drug Optimization. , 2020, Journal of medicinal chemistry.

[5]  M. Lenardo,et al.  A guide to cancer immunotherapy: from T cell basic science to clinical practice , 2020, Nature Reviews Immunology.

[6]  J. Hunt,et al.  Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillance , 2019, PloS one.

[7]  BinQing Wei,et al.  Hematopoietic Progenitor Kinase-1 Structure in a Domain-Swapped Dimer. , 2019, Structure.

[8]  J. Sedelmeier,et al.  Evolution of Small Molecule Kinase Drugs. , 2018, ACS medicinal chemistry letters.

[9]  K. Duffy,et al.  CHAPTER 12:Kinase Inhibition for Immuno-oncology , 2018 .

[10]  I. Mellman,et al.  The Kinase Activity of Hematopoietic Progenitor Kinase 1 Is Essential for the Regulation of T Cell Function. , 2018, Cell reports.

[11]  A. Su,et al.  A genome-wide survey of mutations in the Jurkat cell line , 2017, bioRxiv.

[12]  S. Sawasdikosol,et al.  HPK1 as a novel target for cancer immunotherapy , 2012, Immunologic research.

[13]  E. Casale,et al.  Through the "gatekeeper door": exploiting the active kinase conformation. , 2010, Journal of medicinal chemistry.

[14]  H. Yee,et al.  Hematopoietic progenitor kinase 1 is a critical component of prostaglandin E2-mediated suppression of the anti-tumor immune response , 2009, Cancer Immunology, Immunotherapy.

[15]  T. Tan,et al.  Functional interactions of HPK1 with adaptor proteins , 2005, Journal of cellular biochemistry.

[16]  S. Sawasdikosol,et al.  Hematopoietic progenitor kinase 1 (HPK1) negatively regulates prostaglandin E2-induced fos gene transcription. , 2003, Blood.

[17]  M. C. Hu,et al.  Involvement of Hematopoietic Progenitor Kinase 1 in T Cell Receptor Signaling* , 2001, The Journal of Biological Chemistry.

[18]  P. Mackenzie,et al.  Structural and functional studies of UDP-glucuronosyltransferases. , 1999, Drug metabolism reviews.

[19]  T. Tan,et al.  Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell–mediated immune responses , 2007, Nature Immunology.